Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
BioMarin Pharmaceutical Inc.'s quarterly P/E stands at 26.2x, up 40.6% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has expanded 23.2% YoY to 16.8x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 30.07 | 26.15 | — | — | 11.17 | 18.60 | 25.68 | 31.95 | 37.42 | 47.47 | 219.14 | 105.33 | 74.72 |
| — | +40.6% | — | — | -70.1% | -60.8% | -88.3% | -69.7% | -49.9% | -49.2% | — | — | -45.9% | |
| P/S Ratio | 3.23 | 3.64 | 3.35 | 3.35 | 3.27 | 4.66 | 4.32 | 4.65 | 5.80 | 6.71 | 7.16 | 7.27 | 7.10 |
| — | -21.8% | -22.4% | -27.9% | -43.5% | -30.5% | -39.6% | -36.1% | -18.4% | -15.4% | -20.1% | -6.5% | -2.4% | |
| P/B Ratio | 1.75 | 1.80 | 1.93 | 1.72 | 1.79 | 2.40 | 2.28 | 2.56 | 3.12 | 3.43 | 3.74 | 3.45 | 3.53 |
| — | -25.0% | -15.6% | -32.9% | -42.6% | -30.1% | -38.9% | -25.9% | -11.6% | -15.4% | -10.7% | +0.3% | +2.5% | |
| P/FCF | 14.36 | 13.98 | 49.77 | 7.64 | 16.07 | 22.03 | 19.54 | 17.30 | 42.58 | 338.14 | — | 37.68 | 89.28 |
| — | -36.5% | +154.7% | -55.8% | -62.3% | -93.5% | — | -54.1% | -52.3% | — | — | +16.7% | -35.2% | |
| EV / EBITDA | 15.89 | 16.84 | 27.70 | — | 8.63 | 13.66 | 17.00 | 25.93 | 28.31 | 38.32 | 114.64 | 76.61 | 47.54 |
| — | +23.2% | +63.0% | — | -69.5% | -64.3% | -85.2% | -66.2% | -40.5% | -29.9% | -99.9% | -57.3% | -23.5% | |
| EV / EBIT | 18.26 | 18.84 | — | — | 8.48 | 13.95 | 18.30 | 25.08 | 30.64 | 40.68 | 189.66 | 94.75 | 58.01 |
| — | +35.1% | — | — | -72.3% | -65.7% | -90.4% | -73.5% | -47.2% | -49.3% | — | -93.5% | -43.9% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
BioMarin Pharmaceutical Inc.'s operating margin was 18.0% in Q1 2026, up 8.9 pp QoQ and down 12.1 pp YoY. This marks the 3rd consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of 13.6% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin contracted 6.4% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.1% | 74.6% | 66.3% | 82.0% | 81.8% | 79.7% | 81.8% | 74.7% | 81.7% | 80.7% | 79.0% | 78.0% | 78.1% |
| — | -6.4% | -19.0% | +9.7% | +0.2% | -1.3% | +3.5% | -4.2% | +4.6% | +4.4% | +3.6% | +1.3% | +1.5% | |
| Operating Margin | 16.6% | 18.0% | 9.1% | -6.0% | 33.5% | 30.0% | 21.6% | 15.3% | 16.9% | 13.6% | 2.2% | 5.3% | 11.0% |
| — | -40.2% | -58.0% | -139.4% | +98.3% | +120.4% | +881.6% | +190.9% | +53.6% | +30.3% | +148.3% | +1197.8% | +50.2% | |
| Net Margin | 10.8% | 13.8% | -5.3% | -4.0% | 29.1% | 24.9% | 16.7% | 14.2% | 15.1% | 13.7% | 3.2% | 6.9% | 9.4% |
| — | -44.7% | -131.9% | -127.8% | +93.6% | +82.4% | +430.3% | +104.8% | +59.9% | +60.3% | +6909.9% | +627.7% | +81.7% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 5.9% | 1.7% | -0.8% | -0.5% | 4.1% | 3.2% | 2.3% | 2.0% | 2.1% | 1.8% | 0.4% | 0.8% | 1.2% |
| — | -47.1% | -134.0% | -125.7% | +96.7% | +83.3% | +445.4% | +137.7% | +74.3% | +61.1% | +7763.0% | +669.1% | +90.9% | |
| ROA | 4.8% | 1.3% | -0.6% | -0.4% | 3.3% | 2.6% | 1.8% | 1.5% | 1.5% | 1.3% | 0.3% | 0.6% | 0.9% |
| — | -50.4% | -133.9% | -126.8% | +114.2% | +103.2% | +502.6% | +151.5% | +78.3% | +62.8% | +7782.1% | +665.5% | +90.3% | |
| ROIC | 7.4% | 1.9% | 1.1% | -0.6% | 3.9% | 3.1% | 2.3% | 1.6% | 1.7% | 1.2% | 0.2% | 0.4% | 0.9% |
| — | -39.5% | -51.6% | -140.7% | +131.4% | +154.3% | +1018.4% | +260.4% | +75.5% | +34.2% | +154.6% | +1301.1% | +59.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
BioMarin Pharmaceutical Inc.'s Debt/EBITDA ratio is 9.3x, up from 6.4x last quarter — elevated, raising questions about debt serviceability. The current ratio has improved 5.2% YoY to 5.81x, strengthening the short-term liquidity position. Debt/Equity has risen for 3 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.11 | 0.23 | 0.11 | 0.10 | 0.10 | 0.10 | 0.11 | 0.11 | 0.21 | 0.22 | 0.22 | 0.22 | 0.23 |
| — | +121.6% | -0.9% | -10.4% | -51.8% | -51.9% | -51.9% | -50.2% | -9.0% | -7.9% | -6.8% | -6.4% | -5.7% | |
| Debt / EBITDA | 1.05 | 9.28 | 6.44 | — | 2.04 | 2.45 | 3.26 | 4.53 | 7.48 | 9.47 | 26.67 | 19.49 | 12.02 |
| — | +279.4% | +97.7% | — | -72.7% | -74.2% | -87.8% | -76.7% | -37.7% | -23.1% | -99.9% | -60.0% | -29.1% | |
| Current Ratio | 5.21 | 5.81 | 5.21 | 4.83 | 5.56 | 5.52 | 5.33 | 4.27 | 3.05 | 2.74 | 2.51 | 2.54 | 4.94 |
| — | +5.2% | -2.2% | +13.0% | +82.1% | +101.2% | +112.0% | +68.1% | -38.2% | -42.2% | -46.2% | -50.7% | -8.8% | |
| Quick Ratio | 3.50 | 4.20 | 3.50 | 3.10 | 3.60 | 3.49 | 3.29 | 2.62 | 1.95 | 1.70 | 1.57 | 1.65 | 3.31 |
| — | +20.3% | +6.2% | +18.0% | +85.2% | +105.6% | +109.7% | +58.7% | -41.2% | -47.2% | -50.2% | -53.3% | -10.4% | |
| Interest Coverage | 45.27 | 9.20 | -8.77 | -9.21 | 112.19 | 84.16 | 66.70 | 46.30 | 37.97 | 30.76 | 4.07 | 12.03 | 19.86 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying BMRN stock.
BioMarin Pharmaceutical Inc.'s current P/E is 30.1x. The average P/E over the last 2 quarters is 18.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
BioMarin Pharmaceutical Inc.'s current operating margin is 16.6%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking BioMarin Pharmaceutical Inc.'s business trajectory between earnings reports.